Invikafusp alfa has recently demonstrated single agent clinical activity across different PD-1 resistant cancers in the ongoing START-001 Phase1/2 clinical study The collaboration plans to evaluate the combination of Marengo’s first-in-class TCR Vβ selective dual T cell agonist, STAR0602…